AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7960981 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (all patients)
Number of subjects: 174
Study 7960981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive radiotherapy
Number of subjects: 174
Study 3232904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose absorbers
Number of subjects: 64
Study 3232904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 31543353 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-based multicomponent interventions
Number of subjects: 262
Study 31543353 — intervention group
Group type: COMPARATOR
Intervention: Health education alone (Control)
Number of subjects: 262
Study 28520955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + bupivacaine (10 mg)
Number of subjects: 90
Study 28520955 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Number of subjects: 90
Study 28520955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Number of subjects: 90
Study 27241157 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education for 6 months
Number of subjects: 391
Study 27241157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 391
Study 24655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention
Number of subjects: 62
Study 24655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural respect and recognition of worth and dignity
Number of subjects: 62
Study 24655682 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential similarities between researcher and participants
Number of subjects: 62
Study 22014541 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW) for 12 weeks, followed by etanercept 50 mg once weekly (QW)
Number of subjects: 124
Study 22014541 — intervention group
Group type: COMPARATOR
Intervention: SC placebo BIW for 12 weeks, followed by etanercept 50 mg BIW for 12 weeks
Number of subjects: 124
Study 20197099 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-learning negative emotion (watching a 3-min negative video clip)
Number of subjects: 0
Study 20197099 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-learning positive emotion (watching a 3-min positive video clip)
Number of subjects: 0
Study 20197099 — intervention group
Group type: COMPARATOR
Intervention: Calm and relaxed condition (control group)
Number of subjects: 0
Study 17389703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose propylthiouracil (PTU)
Number of subjects: 0
Study 17389703 — intervention group
Group type: EXPERIMENTAL
Intervention: PTU plus KI
Number of subjects: 0
Study 17389703 — intervention group
Group type: EXPERIMENTAL
Intervention: PTU plus sodium ipodate
Number of subjects: 0
Study 16271575 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) for 60 minutes a day, 5 times a week for 4 weeks
Number of subjects: 5
Study 12729940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 12729940 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 12729940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10639692 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 3-g glucose tablets
Number of subjects: 38
Study 10639692 — intervention group
Group type: COMPARATOR
Intervention: Four matched placebo tablets
Number of subjects: 38
Study 7488817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with multiple low doses of porcine surfactant
Number of subjects: 256
Study 7488817 — intervention group
Group type: COMPARATOR
Intervention: Rescue therapy
Number of subjects: 256
Study 1935927 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (bolus 1.5 mg kg‐1, infusion 9 mg kg‐1 h‐1 for 10 min thereafter 6 mg kg‐1 h‐1)
Number of subjects: 21
Study 1935927 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (bolus 0.10 mg kg‐1, infusion 3 mg kg‐1 h‐1 reduced to 0.6 mg kg‐1 h‐1)
Number of subjects: 21
Study 7047681 — intervention group
Group type: EXPERIMENTAL
Intervention: ADW hepatitis B vaccine
Number of subjects: 110
Study 7047681 — intervention group
Group type: COMPARATOR
Intervention: AYW hepatitis B vaccine
Number of subjects: 110
Study 31331219 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 350
Study 31331219 — intervention group
Group type: COMPARATOR
Intervention: OCT
Number of subjects: 350
Study 29969826 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus (TAC)
Number of subjects: 115
Study 29969826 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS) with tacrolimus (TAC)
Number of subjects: 115
Study 29969826 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 115
Study 29969826 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 115
Study 26337521 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic tube (SPT)
Number of subjects: 62
Study 26337521 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheter (UC)
Number of subjects: 62
Study 24501241 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 41
Study 24501241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24501241 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (early and delayed groups)
Number of subjects: 41
Study 22147616 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 mIBG SPECT
Number of subjects: 1118
Study 22147616 — intervention group
Group type: EXPERIMENTAL
Intervention: Order subsets expectation maximization
Number of subjects: 1118
Study 22147616 — intervention group
Group type: COMPARATOR
Intervention: Planar H/M
Number of subjects: 1118
Study 20850069 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFV (high intakes of fruits and vegetables)
Number of subjects: 68
Study 20850069 — intervention group
Group type: COMPARATOR
Intervention: LOFAT (restrictive messages to limit consumption of high-fat foods)
Number of subjects: 68
Study 18694217 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based portfolio system for feedback
Number of subjects: 0
Study 18694217 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional feedback methods)
Number of subjects: 0
Study 18694217 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based portfolio system
Number of subjects: 0
Study 15722818 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in patients with COPD
Number of subjects: 50
Study 15722818 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET imaging in patients without COPD
Number of subjects: 50
Study 12150684 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antifungal agents (new agents with enhanced activity against non-C. albicans and Aspergillus species)
Number of subjects: 0
Study 12150684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated older broad-spectrum antifungals
Number of subjects: 0
Study 9485122 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (defined as claudication, peripheral vascular surgery, abdominal aortic aneurysm, history of cerebral ischemia, or carotid disease)
Number of subjects: 1816
Study 9485122 — intervention group
Group type: COMPARATOR
Intervention: No noncoronary atherosclerosis
Number of subjects: 1816
Study 9485122 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (surgery)
Number of subjects: 1816
Study 9485122 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (angioplasty)
Number of subjects: 1816
Study 7610928 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (aerobics and weight training)
Number of subjects: 127
Study 7610928 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 127
Study 2201960 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (15-20 mg/L)
Number of subjects: 0
Study 835370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 6-propylthiouracil (PTU) in a fasting state
Number of subjects: 8
Study 835370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 6-propylthiouracil (PTU) with a standardized breakfast
Number of subjects: 8
Study 30909946 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting antiplatelet therapy
Number of subjects: 0
Study 30909946 — intervention group
Group type: COMPARATOR
Intervention: Avoiding antiplatelet therapy
Number of subjects: 0
Study 28049624 — intervention group
Group type: EXPERIMENTAL
Intervention: Web 2.0 intervention
Number of subjects: 504
Study 28049624 — intervention group
Group type: COMPARATOR
Intervention: Web 1.0 intervention
Number of subjects: 504
Study 28049624 — intervention group
Group type: COMPARATOR
Intervention: Logbook intervention
Number of subjects: 504
Study 25973670 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow incentive spirometry
Number of subjects: 137
Study 25973670 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 137
Study 25973670 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume incentive spirometry
Number of subjects: 137
Study 25973670 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study 23578454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120
Study 23578454 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120
Study 20689306 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased vocal intensity in non-cleft group
Number of subjects: 0
Study 20689306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered pitch level
Number of subjects: 0
Study 19054187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including pain assessment at rest and with physical therapy, physician protocols for standing analgesia and preemptive analgesia before PT.
Number of subjects: 249
Study 19054187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 249
Study 17089080 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training Program
Number of subjects: 66
Study 14718877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (resin-modified glass ionomer cement)
Number of subjects: 14
Study 14718877 — intervention group
Group type: COMPARATOR
Intervention: Concise (composite resin, control group)
Number of subjects: 14
Study 11354236 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 50 mg b.d. for 6 weeks
Number of subjects: 113
Study 11354236 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine 100 mg b.d. for 6 weeks
Number of subjects: 113
Study 9816524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low activity 32P Palmaz-Schatz and BX radioactive stents
Number of subjects: 170
Study 9816524 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 170
Study 8549036 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg once daily for 5 days)
Number of subjects: 10
Study 8549036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2107653 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 25 mg
Number of subjects: 6
Study 2107653 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 50 mg
Number of subjects: 6
Study 2107653 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1‐29) NH2, 100 micrograms
Number of subjects: 6
Study 7358942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lodoxamide ethyl
Number of subjects: 10
Study 7358942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg lodoxamide ethyl
Number of subjects: 10
Study 7358942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31152534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex massage procedures and controlled physical training (10 sessions)
Number of subjects: 50
Study 31152534 — intervention group
Group type: COMPARATOR
Intervention: Individually selected training (control group)
Number of subjects: 50
Study 27198588 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) flapless approach
Number of subjects: 40
Study 27198588 — intervention group
Group type: COMPARATOR
Intervention: Flapped surgery (FS)
Number of subjects: 40
Study 25911562 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium (180 mg/day)
Number of subjects: 141
Study 25911562 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg/day)
Number of subjects: 141
Study 23618777 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (3 μg kg(‐1) h(‐1) reduced to 1.5 μg kg(‐1) h(‐1) after reperfusion for 3 postoperative days)
Number of subjects: 80
Study 23618777 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 80
Study 23618777 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 80
Study 21244548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 287
Study 21244548 — intervention group
Group type: COMPARATOR
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 287
Study 19546455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (60 minutes of bedside counselling, take-home materials, and 7 nurse-initiated counselling calls for 2 months after discharge)
Number of subjects: 276
Study 19546455 — intervention group
Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention (advice from physicians and nurses and 2 pamphlets)
Number of subjects: 276
Study 19546455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 276
Study 19546455 — intervention group
Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention
Number of subjects: 276
Study 19546455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients admitted for CABG
Number of subjects: 276
Study 17693684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron injections
Number of subjects: 16
Study 17693684 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 16
Study 15013506 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in subthalamic nucleus (STN)
Number of subjects: 19
Study 15013506 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in globus pallidus internus (GPi)
Number of subjects: 19
Study 15013506 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 19
Study 15013506 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 19
Study 11776302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU anti‐Xa once daily
Number of subjects: 30
Study 11776302 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 4,000 IU anti‐Xa once daily
Number of subjects: 30
Study 11776302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 50 IU/kg anti‐Xa (average dose 3,650 anti‐Xa units) once daily
Number of subjects: 30
Study 8827777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based formula
Number of subjects: 20
Study 8827777 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate formula
Number of subjects: 20
Study 8827777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 20
Study 1593356 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal volumes during the first 4 days of life (NICU 1)
Number of subjects: 223
Study 1593356 — intervention group
Group type: COMPARATOR
Intervention: Colloidal volumes during the first 4 days of life (NICU 3)
Number of subjects: 223
Study 1593356 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of patent ductus arteriosus (NICU 1)
Number of subjects: 223
Study 1593356 — intervention group
Group type: COMPARATOR
Intervention: Signs of patent ductus arteriosus (NICU 2)
Number of subjects: 223
Study 1593356 — intervention group
Group type: COMPARATOR
Intervention: Signs of patent ductus arteriosus (NICU 3)
Number of subjects: 223
Study 1593356 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum inspired oxygen fraction during the first 4 days
Number of subjects: 223
Study 1593356 — intervention group
Group type: COMPARATOR
Intervention: Maximum arterial oxygen tension (NICU 3)
Number of subjects: 223
Study 1593356 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end‐expiratory pressure
Number of subjects: 223
Study 6239670 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 0
Study 6239670 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation plus operant conditioning
Number of subjects: 0
Study 6239670 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 0
Study 6239670 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups (applied relaxation and applied relaxation plus operant conditioning)
Number of subjects: 0
Study 30260488 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental very high-protein (37%) and low-carbohydrate (29%) EN formula
Number of subjects: 105
Study 30260488 — intervention group
Group type: COMPARATOR
Intervention: Control high-protein (25%) and conventional-carbohydrate (45%) EN formula
Number of subjects: 105
Study 30260488 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental very high-protein and low-carbohydrate EN formula
Number of subjects: 105
Study 30260488 — intervention group
Group type: COMPARATOR
Intervention: Control high-protein and conventional-carbohydrate EN formula
Number of subjects: 105
Study 29249371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to right dlPFC
Number of subjects: 71
Study 29249371 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation to right dlPFC
Number of subjects: 71
Study 29249371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to left dlPFC
Number of subjects: 71
Study 29249371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to left dlPFC in older adults
Number of subjects: 71
Study 27055275 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-based approach using RDTs (RDT arm)
Number of subjects: 3046
Study 27055275 — intervention group
Group type: COMPARATOR
Intervention: Presumptive approach using clinical judgment (CJ arm)
Number of subjects: 3046
Study 24912736 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (education on diet and exercise, stress coping methods, relaxation breathing, and progressive muscle relaxation)
Number of subjects: 22
Study 24912736 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no additional intervention)
Number of subjects: 22
Study 22513288 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal A breast cancer
Number of subjects: 281
Study 22513288 — intervention group
Group type: COMPARATOR
Intervention: Core basal phenotype (CBP) breast cancer
Number of subjects: 281
Study 20044806 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 1347
Study 20044806 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 1347
Study 16864983 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (Premarin 0.625 mg)
Number of subjects: 30
Study 16864983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (Livial 2.5 mg)
Number of subjects: 30
Study 16864983 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal menstrual cycles)
Number of subjects: 30
Study 16244510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle/stress management program (n = 48)
Number of subjects: 101
Study 16244510 — intervention group
Group type: COMPARATOR
Intervention: Written advice (n = 53)
Number of subjects: 101
Study 12403882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 12
Study 12403882 — intervention group
Group type: COMPARATOR
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12
Study 10025391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 54
Study 10025391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 54
Study 10025391 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 54
Study 8804470 — intervention group
Group type: COMPARATOR
Intervention: PNC + PLC (Placebo)
Number of subjects: 80
Study 8804470 — intervention group
Group type: EXPERIMENTAL
Intervention: PNC + DXM (Dexamethasone)
Number of subjects: 80
Study 1777550 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 23
Study 1777550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 23
Study 1777550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6127224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynorphin‐(1‐13) at a dose of 60 micrograms/kg body weight
Number of subjects: 12
Study 6127224 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 31219276 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance at Session 3, 4, or 5
Number of subjects: 144
Study 31219276 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-therapist effect of the alliance
Number of subjects: 144
Study 31219276 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-therapist (client) effect of the alliance
Number of subjects: 144
Study 28974553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogenic UC‐MSCs (1×10^6 cells/kg)
Number of subjects: 30
Study 28974553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogenic UC‐MSCs
Number of subjects: 30
Study 28974553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26335982 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-acknowledged alerts
Number of subjects: 171
Study 26335982 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCR-acknowledged alerts
Number of subjects: 171
Study 26335982 — intervention group
Group type: COMPARATOR
Intervention: Preintervention alerts
Number of subjects: 171